Autres langues Dyne Therapeutics, Inc.

Actions

DYN

US26818M1080

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 26/04/2024			Varia. 5j.	Varia. 1 janv.
24,73 ^USD	+4,37%		+3,65%	+85,94%

25/03	Le président et chef de la direction de Dyne Therapeutics, Joshua Brumm, démissionne, John Cox lui succède ; les actions chutent de 7 % avant la cloche.	MT
25/03	Dyne Therapeutics, Inc. annonce des changements au sein de sa direction	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer	27/03
Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium	27/03
Dyne Therapeutics President, CEO Joshua Brumm Resigns, John Cox Named Successor; Shares Drop 7% Pre-Bell	25/03
Dyne Therapeutics Announces CEO Transition	25/03
Dyne Therapeutics, Inc. Announces Management Changes	25/03
Dyne Therapeutics, Inc. Announces Chief Executive Officer Changes	25/03
Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days	13/03
Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days	13/03
Dyne Therapeutics Insider Sold Shares Worth $1,398,347, According to a Recent SEC Filing	05/03
Dyne Therapeutics's Q4 Net Loss Widens; Shares Down Pre-Bell	05/03
Dyne Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	05/03
Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights	05/03
Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights	05/03
Dyne Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	05/03
Dyne Therapeutics Insider Sold Shares Worth $2,895,519, According to a Recent SEC Filing	04/03
Dyne Therapeutics Insider Sold Shares Worth $811,865, According to a Recent SEC Filing	04/03
Dyne Therapeutics Insider Sold Shares Worth $357,296, According to a Recent SEC Filing	04/03
Dyne Therapeutics Insider Sold Shares Worth $19,626,903, According to a Recent SEC Filing	29/02
Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference	14/02
Dyne Therapeutics to Present at February Investor Conferences	01/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Dyne Therapeutics, Inc.

Actions

DYN

US26818M1080

Autres langues

Filtres